ProQR Therapeutics (PRQR) Change in Working Capital (2013 - 2025)

ProQR Therapeutics has disclosed Change in Working Capital across 13 years of filings, most recently posting -$3.6 million for Q3 2025.

• Change in Working Capital for Q3 2025 came in at -$3.6 million, down 392.95% year-over-year; the trailing twelve-month figure through Sep 2025 was -$10.8 million (up 90.77% YoY), and the FY2023 annual result was -$52.7 million, down 11554.26% from the prior year.
• Change in Working Capital came in at -$3.6 million for Q3 2025 at ProQR Therapeutics, down from -$1.3 million in the prior quarter.
• In the past five years, Change in Working Capital ranged from a high of $56.1 million in Q1 2023 to a low of -$102.9 million in Q4 2023.
• The 5-year median for Change in Working Capital is -$1.2 million (2025), against an average of -$2.8 million.
• Peak annual rise in Change in Working Capital reached 1621.0% in 2021, while the deepest fall reached 47182.62% in 2021.
• ProQR Therapeutics' Change in Working Capital stood at $22.1 million in 2021, then sank by 104.68% to -$1.0 million in 2022, then plunged by 9834.52% to -$102.9 million in 2023, then surged by 101.19% to $1.2 million in 2024, then sank by 392.95% to -$3.6 million in 2025.
• The last three Change in Working Capital figures came in at -$3.6 million (Q3 2025), -$1.3 million (Q2 2025), and -$7.1 million (Q1 2025), per Business Quant data.